MGNX vs. RXRX

Last updated Jun 5, 2026

MGNX (MacroGenics, Inc.) and RXRX (Recursion Pharmaceuticals, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, MGNX returned -30.92%/yr vs -33.59%/yr for RXRX. At a 0.33 correlation, their price movements are largely independent.

Performance

MGNX vs. RXRX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in MacroGenics, Inc. (MGNX) and Recursion Pharmaceuticals, Inc. (RXRX). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, MGNX achieves a 163.98% return, which is significantly higher than RXRX's -7.09% return.

MGNX

• 1D: 1.19%
• 1M: 34.92%
• YTD: 163.98%
• 6M: 207.97%
• 1Y: 183.33%
• 3Y*: -5.40%
• 5Y*: -30.92%
• 10Y*: -17.24%

RXRX

• 1D: 9.51%
• 1M: 12.76%
• YTD: -7.09%
• 6M: -22.76%
• 1Y: -22.61%
• 3Y*: -23.33%
• 5Y*: -33.59%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

MGNX vs. RXRX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
MGNX MacroGenics, Inc.	163.98%	-50.46%	-66.22%	43.37%	-58.19%	-49.58%
RXRX Recursion Pharmaceuticals, Inc.	-7.09%	-39.50%	-31.44%	27.89%	-54.99%	-45.27%

Correlation

The correlation between MGNX and RXRX is 0.35, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.35
Correlation (3Y) Calculated over the trailing 3-year period	0.34
Correlation (5Y) Calculated over the trailing 5-year period	0.34
Correlation (All Time) Calculated using the full available price history since Apr 19, 2021	0.33

Fundamentals

Market Cap MGNX : $269.66M RXRX : $2.01B
EPS MGNX : -$1.11 RXRX : -$1.17
PS Ratio MGNX : 1.71 RXRX : 27.52
PB Ratio MGNX : 12.72 RXRX : 1.96
Total Revenue (TTM) MGNX : $157.08M RXRX : $66.29M
Gross Profit (TTM) MGNX : $98.53M RXRX : -$22.83M
EBITDA (TTM) MGNX : -$59.93M RXRX : -$505.90M

Return for Risk

MGNX vs. RXRX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

MGNX

MGNX Risk / Return Rank: 88
MGNX Sharpe Ratio Rank: 87
MGNX Sortino Ratio Rank: 90
MGNX Omega Ratio Rank: 84
MGNX Calmar Ratio Rank: 92
MGNX Martin Ratio Rank: 89

RXRX

RXRX Risk / Return Rank: 30
RXRX Sharpe Ratio Rank: 28
RXRX Sortino Ratio Rank: 31
RXRX Omega Ratio Rank: 31
RXRX Calmar Ratio Rank: 29
RXRX Martin Ratio Rank: 30

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

MGNX vs. RXRX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for MacroGenics, Inc. (MGNX) and Recursion Pharmaceuticals, Inc. (RXRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	MGNX	RXRX	Difference
Sharpe ratio: Return per unit of total volatility	1.94	-0.31	+2.25
Sortino ratio: Return per unit of downside risk	3.26	0.01	+3.25
Omega ratio: Gain probability vs. loss probability	1.35	1.00	+0.35
Calmar ratio: Return relative to maximum drawdown	5.40	-0.39	+5.79
Martin ratio: Return relative to average drawdown	11.09	-0.64	+11.73
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

MGNX vs. RXRX - Sharpe Ratio Comparison

The current MGNX Sharpe Ratio is 1.94, which is higher than the RXRX Sharpe Ratio of -0.31. The chart below compares the historical Sharpe Ratios of MGNX and RXRX, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	MGNX	RXRX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.94	-0.31	+2.25
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.33	-0.36	+0.03
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.15	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.12	-0.36	+0.24

Drawdowns

MGNX vs. RXRX - Drawdown Comparison

The maximum MGNX drawdown since its inception was -97.36%, roughly equal to the maximum RXRX drawdown of -93.13%. Use the drawdown chart below to compare losses from any high point for MGNX and RXRX.

Drawdown Indicators

	MGNX	RXRX	Difference
Max Drawdown Largest peak-to-trough decline	-97.36%	-93.13%	-4.23%
Max Drawdown (1Y) Largest decline over 1 year	-34.16%	-58.17%	+24.01%
Max Drawdown (3Y) Largest decline over 3 years	-95.06%	-82.09%	-12.97%
Max Drawdown (5Y) Largest decline over 5 years	-96.31%	-93.13%	-3.18%
Max Drawdown (10Y) Largest decline over 10 years	-97.02%	—	—
Current Drawdown Current decline from peak	-89.43%	-90.81%	+1.38%
Average Drawdown Average peak-to-trough decline	-58.36%	-75.36%	+17.00%
Ulcer Index Depth and duration of drawdowns from previous peaks	16.60%	35.28%	-18.68%

Volatility

MGNX vs. RXRX - Volatility Comparison

MacroGenics, Inc. (MGNX) has a higher volatility of 28.90% compared to Recursion Pharmaceuticals, Inc. (RXRX) at 20.35%. This indicates that MGNX's price experiences larger fluctuations and is considered to be riskier than RXRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	MGNX	RXRX	Difference
Volatility (1M) Calculated over the trailing 1-month period	28.90%	20.35%	+8.55%
Volatility (6M) Calculated over the trailing 6-month period	62.76%	45.51%	+17.25%
Volatility (1Y) Calculated over the trailing 1-year period	95.30%	74.04%	+21.26%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	92.97%	93.56%	-0.59%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	115.73%	93.66%	+22.07%

Dividends

MGNX vs. RXRX - Dividend Comparison

Neither MGNX nor RXRX has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both MGNX and RXRX in my portfolio?

MGNX and RXRX have a correlation of 0.35, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, MGNX or RXRX?

MGNX has higher volatility (28.90%) compared to RXRX (20.35%). In terms of maximum drawdown, MGNX dropped -97.36% vs RXRX's -93.13%.

Which has better risk-adjusted returns?

MGNX currently has the higher Sharpe Ratio (1.94 vs -0.31), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.